Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Recruiting · Phase 1, Phase 2 · NCT06590857
Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer With Bone Involvement, Bone Metastases in Subjects With Advanced Breast Cancer, ER-Positive HER2-Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Hormone-sensitive Metastatic Breast Cancer, Hormone-Sensitive Breast Cancer
At a glance
- Research payments reported, 2025
- $1.2M
- U.S. investigators named
- 20
- Sites paid
- 19
- Planned or actual enrollment
- 64
About the trial
- Sponsor
- RayzeBio, Inc.
- Tested
- RYZ101 (drug), Standard of Care Endocrine Therapy (drug)
- Dates
- Started 2024-07-19; completion 2033-11
- Results posted
- Not yet
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
From ClinicalTrials.gov, last updated 2026-10-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $1.2M in research payments for this study in 2025 (27 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Brenda Ernst, M.D. Hematology & Oncology · Scottsdale, AZ
- Teresa L. Helsten, M.D. Hematology & Oncology · La Jolla, CA
- Nicolaos J. Palaskas, M.D. Hematology & Oncology · Santa Monica, CA
- Sara D. Robinson, M.D. Hematology & Oncology · Longmont, CO
- Rohit R. Rao, M.D Hematology & Oncology · Jacksonville, FL
- Kathy D. Miller, MD Hematology & Oncology · Indianapolis, IN
- Amol M. Takalkar, M.D. Nuclear Medicine · Shreveport, LA
- Erica L. Mayer, MD MPH Medical Oncology · Boston, MA
- Geoffrey B. Johnson, MD, PHD Radiology · Rochester, MN
- Nancy Chan, MD Medical Oncology · New York, NY
- Komal Jhaveri Medical Oncology · New York, NY
- Ellis Levine, MD Medical Oncology · Buffalo, NY
- Shimoli Barot, MD Medical Oncology · Cleveland, OH
- Adam M. Brufsky, MD Specialist · Pittsburgh, PA
- Joyce A. O'shaughnessy, MD Medical Oncology · Dallas, TX
- Julio A. Peguero, M.D Medical Oncology · Corpus Christi, TX
- Heloisa P. Soares, M.D. Hematology & Oncology · Salt Lake City, UT
- David A. Buck, M.D. Radiation Oncology · Roanoke, VA
- Michael A. Danso, M.D. Hematology & Oncology · Norfolk, VA
- Jennifer M. Specht Medical Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Mayo Clinic Jacksonville $188,041
- Mayo Clinic Sports Medicine $133,020
- Sarah Cannon Research Institute, Llc $132,055
- University of Utah Hospital and Clinics, UT $95,850
- University of California San Diego $83,683
- Memorial Sloan-Kettering Cancer Center - Cancer $71,629
- NYU School of Medicine $70,035
- University of Washington Medical Ctr, WA $69,515
- Dana-Farber Cancer Institute $65,100
- Mayo Clinic Hospital, AZ $56,849
- Health Research Incorporated $52,050
- Emory University Hospital, GA $50,204
- Ronald Reagan UCLA Medical Center, CA $38,584
- University of Pittsburgh $32,083
- Oncology Consultants, PA $27,698
- Cleveland Clinic, OH $23,280
- Dana Farber Cancer Institute $17,865
- Indiana University $17,480
- Dana-Farber Cancer Institute, Clinical Research Laboratory $17,200
- $5,387
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.